Bank of America’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-84,140
| Closed | -$4.02M | – | 8312 |
|
|
2025
Q3 | $4.02M | Sell |
84,140
-43,231
| -34% | -$1.2M | ﹤0.01% | 4213 |
|
|
2025
Q2 | $2.04M | Sell |
127,371
-109,376
| -46% | -$1.77M | ﹤0.01% | 4758 |
|
|
2025
Q1 | $3.6M | Buy |
236,747
+166,010
| +235% | +$2.66M | ﹤0.01% | 4149 |
|
|
2024
Q4 | $1.43M | Buy |
70,737
+33,028
| +88% | +$832K | ﹤0.01% | 4734 |
|
|
2024
Q3 | $969K | Sell |
37,709
-24,302
| -39% | -$406K | ﹤0.01% | 5077 |
|
|
2024
Q2 | $797K | Buy |
62,011
+54,176
| +691% | +$872K | ﹤0.01% | 5043 |
|
|
2024
Q1 | $179K | Sell |
7,835
-16,176
| -67% | -$570K | ﹤0.01% | 5936 |
|
|
2023
Q4 | $629K | Buy |
24,011
+22,954
| +2,172% | +$459K | ﹤0.01% | 5326 |
|
|
2023
Q3 | $29.7K | Sell |
1,057
-639
| -38% | -$18.7K | ﹤0.01% | 6634 |
|
|
2023
Q2 | $51.5K | Sell |
1,696
-940
| -36% | -$24K | ﹤0.01% | 6455 |
|
|
2023
Q1 | $49.6K | Buy |
2,636
+591
| +29% | +$9.75K | ﹤0.01% | 6513 |
|
|
2022
Q4 | $20.9K | Buy |
2,045
+247
| +14% | +$3.97K | ﹤0.01% | 6724 |
|
|
2022
Q3 | $47K | Buy |
1,798
+629
| +54% | +$22.9K | ﹤0.01% | 6705 |
|
|
2022
Q2 | $53K | Buy |
1,169
+55
| +5% | +$4.34K | ﹤0.01% | 6807 |
|
|
2022
Q1 | $110K | Sell |
1,114
-1,616
| -59% | -$151K | ﹤0.01% | 6812 |
|
|
2021
Q4 | $417K | Buy |
2,730
+645
| +31% | +$95.4K | ﹤0.01% | 6025 |
|
|
2021
Q3 | $283K | Buy |
2,085
+1,680
| +415% | +$230K | ﹤0.01% | 6051 |
|
|
2021
Q2 | $59K | Buy |
+405
| New | +$62K | ﹤0.01% | 6758 |
|
Bank of America's TRML Position: Q4 2025 in Review
Bank of America sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 84,140 shares — an estimated $4.02M sold.
Bank of America first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $4.02M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Bank of America reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Bank of America sold 84,140 Tourmaline Bio shares in Q4 2025, an estimated $4.02M.
- Bank of America first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Bank of America's Tourmaline Bio position peaked at $4.02M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Bank of America's 13F filing for Q4 2025, filed 17 Feb 2026.